Send Inquiry

Request To Call Back

Kyprolis 60 mg Injection

Get a Price/Quote

MOQ : 6 Pieces

Kyprolis 60 mg Injection Specification

Indication
For the treatment of relapsed or refractory multiple myeloma

Origin of Medicine
United States

Pacakaging (Quantity Per Box)
1 vial per box

Life Span
Refer to expiry on the pack

Salt Composition
Carfilzomib 60 mg

Dosage Form
Lyophilized powder for solution for infusion

Brand Name
Kyprolis

Packaging Type
Vial

Drug Type
Prescription Only

Ingredients
Carfilzomib

Physical Form
Powder

Function
Anticancer/Proteasome inhibitor

Recommended For
DOCTOR

Dosage
As prescribed by the physician

Dosage Guidelines
Follow medical advice and prescription guidelines

Suitable For
Adults

Quantity
6 Pieces

Storage Instructions
Store below 25C, protect from light

Adverse Effects
May include anemia, thrombocytopenia, neutropenia, and cardiac events

Instructions for Disposal
Dispose of according to local requirements for cytotoxic agents

Prescription Status
Rx only (requires prescription)

Reconstitution
Required before administration, follow SPC instructions

Patient Information Leaflet
Supplied with each pack

Appearance
Lyophilized white to off-white powder

Contraindications
Hypersensitivity to Carfilzomib or excipients

Intended Use
To be administered by qualified healthcare professionals only

Marketed By
Amgen Biotech

Therapeutic Class
Antineoplastic agents

Warning
For hospital use only; keep out of reach of children

Route of Administration
Intravenous

ATC Code
L01XX45

Shelf Life
As per manufacturer's label

Kyprolis 60 mg Injection Trade Information

Minimum Order Quantity
6 Pieces

Delivery Time
1 Week

About Kyprolis 60 mg Injection

Kyprolis 60 mg injection is a potent medication classified as a protease inhibitor, specifically designed for the treatment of multiple myeloma, a malignancy that affects the blood's plasma cells. By inhibiting the activity of proteases, Kyprolis disrupts critical cellular processes, effectively slowing or halting the proliferation of cancer cells. This innovative therapy is often utilized in combination with other treatments to enhance efficacy and improve patient outcomes. Patients receiving Kyprolis may experience side effects, including fatigue, diarrhea, and potential cardiovascular issues, necessitating careful monitoring by healthcare professionals. It is crucial for patients to discuss their complete medical history and any other medications they are taking with their doctor prior to starting this treatment. As with any cancer therapy, the benefits and risks should be weighed thoughtfully to ensure the best possible approach to managing multiple myeloma. If you or a loved one is considering Kyprolis, consult with a healthcare provider to understand its role in your treatment plan.

Highly Targeted Anticancer Therapy

Kyprolis works by selectively inhibiting proteasomes, essential protein complexes in cancer cells, which helps halt the growth of multiple myeloma. Its targeted mechanism makes it a significant option for patients experiencing relapse or resistance to other treatments. This therapy is strictly administered under professional supervision for safety and optimum efficacy.

Strict Professional Administration

Administration of Kyprolis is limited to infusion by healthcare professionals in a hospital setting. Reconstitution is required prior to infusion, following the specific protocol outlined in the SPC. Handling precautions and disposal procedures are rigorously maintained due to the cytotoxic nature of the medication.

FAQ's of Kyprolis 60 mg Injection:

Q: How is Kyprolis 60 mg Injection administered?

A: Kyprolis is administered intravenously by qualified healthcare professionals, following reconstitution as per the SPC instructions. It should only be given in a hospital setting.

Q: What is Kyprolis 60 mg Injection used for?

A: Kyprolis is indicated for the treatment of adults with relapsed or refractory multiple myeloma. It helps target and inhibit cancer cell growth, improving outcomes for suitable patients.

Q: When should Kyprolis not be used?

A: Kyprolis must not be used in patients who have hypersensitivity to carfilzomib or any of its excipients. It is also not intended for use in children and should only be administered as prescribed by a physician.

Q: Where should Kyprolis vials be stored before use?

A: Store the vials below 25C and protect them from light. Always refer to the manufacturer's label for the precise shelf life and storage guidelines.

Q: What is the process for preparing Kyprolis for administration?

A: Kyprolis requires reconstitution before intravenous infusion. The preparation must be performed by professionals, strictly adhering to the SPC instructions to ensure correct dosing and patient safety.

Q: How should unused Kyprolis or waste material be disposed of?

A: Unused product or waste should be disposed of in accordance with local regulations for cytotoxic agents. This ensures environmental safety and compliance with healthcare standards.

Q: What are the potential benefits of using Kyprolis for multiple myeloma?

A: Kyprolis offers an advanced therapeutic option for patients with relapsed or refractory multiple myeloma, potentially improving response rates and prolonging progression-free survival when previous treatments have failed.

Tell us about your requirement